{"url_path":"/sec/kapa/8-k/2026-05-18/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-024082-index.html","accession_number":"0001493152-26-024082","cik":"0001962011","ticker":"KAPA","issuer_name":"Kairos Pharma, LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1962011/0001493152-26-024082-index.html","primary_entity_key":"0001962011","primary_entity_name":"Kairos Pharma, LTD."},"word_count":85,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\n**Exhibit\nNo.**\n \n**Description\nof Document**\n\n99.1\n \n[Investor Presentation](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant\nto the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf\nby the undersigned hereunto duly authorized.\n\n \n\nDate:\nMay 18, 2026\n**KAIROS\nPHARMA, LTD.**\n\n \n \n \n\n \nBy:\n*/s/\nJohn S. Yu*\n\n \n \nJohn\nS. Yu\n\n \n \nChief\nExecutive Officer"}